Santhera Pharma H1 revenue rises 101% on AGAMREE sales; 2026 guidance kept at CHF 80-90 mln

Santhera said H1 revenue rose 101% year-on-year, with product sales up 48% and net loss narrowing to CHF 21.5 mln from CHF 38.8 mln. It kept 2026 revenue guidance at CHF 80-90 mln and expects product sales to grow by more than 50% in 2026.